1G84
 
 | | THE SOLUTION STRUCTURE OF THE C EPSILON2 DOMAIN FROM IGE | | Descriptor: | IMMUNOGLOBULIN E | | Authors: | McDonnell, J.M, Cowburn, D, Gould, H.J, Sutton, B.J, Calvert, R, Beavil, R.E, Beavil, A.J, Henry, A.J. | | Deposit date: | 2000-11-16 | | Release date: | 2001-05-16 | | Last modified: | 2021-10-27 | | Method: | SOLUTION NMR | | Cite: | The structure of the IgE Cepsilon2 domain and its role in stabilizing the complex with its high-affinity receptor FcepsilonRIalpha.
Nat.Struct.Biol., 8, 2001
|
|
1O0V
 | | The crystal structure of IgE Fc reveals an asymmetrically bent conformation | | Descriptor: | GLYCEROL, Immunoglobulin heavy chain epsilon-1, SULFATE ION, ... | | Authors: | Wan, T, Beavil, R.L, Fabiane, S.M, Beavil, A.J, Sohi, M.K, Keown, M, Young, R.J, Henry, A.J, Owens, R.J, Gould, H.J, Sutton, B.J. | | Deposit date: | 2002-09-06 | | Release date: | 2002-09-18 | | Last modified: | 2023-12-27 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | The crystal structure of IgE Fc reveals an asymmetrically bent conformation
NAT.IMMUNOL., 3, 2002
|
|
5G64
 | | The complex between human IgE-Fc and two anti-IgE Fab fragments | | Descriptor: | FAB FRAGMENT, IG EPSILON CHAIN C REGION, alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose | | Authors: | Davies, A.M, Allan, E.G, Keeble, A.H, Delgado, J, Cossins, B.P, Mitropoulou, A.N, Pang, M.O.Y, Ceska, T, Beavil, A.J, Craggs, G, Westwood, M, Henry, A.J, McDonnell, J.M, Sutton, B.J. | | Deposit date: | 2016-06-14 | | Release date: | 2017-05-03 | | Last modified: | 2024-01-10 | | Method: | X-RAY DIFFRACTION (3.715 Å) | | Cite: | Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.
J. Biol. Chem., 292, 2017
|
|
6TCN
 | | Crystal structure of the omalizumab Fab - crystal form II | | Descriptor: | 1,2-ETHANEDIOL, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, DI(HYDROXYETHYL)ETHER, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCP
 | | Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form II | | Descriptor: | DI(HYDROXYETHYL)ETHER, GLYCEROL, Omalizumab Fab Leu158Pro light chain mutant, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCR
 | | Crystal structure of the omalizumab Fab Ser81Arg, Gln83Arg and Leu158Pro light chain mutant | | Descriptor: | 1,2-ETHANEDIOL, DI(HYDROXYETHYL)ETHER, Omalizumab Fab Ser81Arg, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.45 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCO
 | | Crystal structure of the omalizumab Fab Leu158Pro light chain mutant - crystal form I | | Descriptor: | 1,2-ETHANEDIOL, Omalizumab Fab Leu158Pro light chain mutant, SULFATE ION | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.8 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCM
 | | Crystal structure of the omalizumab Fab - crystal form I | | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, GLYCEROL, Omalizumab Fab, ... | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (1.85 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCS
 | | Crystal structure of the omalizumab scFv | | Descriptor: | DI(HYDROXYETHYL)ETHER, Omalizumab scFv | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
6TCQ
 | | Crystal structure of the omalizumab Fab Ser81Arg and Gln83Arg light chain mutant | | Descriptor: | GLYCEROL, Omalizumab Fab Ser81Arg and Gln83Arg light chain mutant | | Authors: | Mitropoulou, A.N, Ceska, T, Beavil, A.J, Henry, A.J, McDonnell, J.M, Sutton, B.J, Davies, A.M. | | Deposit date: | 2019-11-06 | | Release date: | 2020-03-18 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.05 Å) | | Cite: | Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization.
Acta Crystallogr.,Sect.F, 76, 2020
|
|
2M2D
 | | Human programmed cell death 1 receptor | | Descriptor: | Programmed cell death protein 1 | | Authors: | Veverka, V, Cheng, X, Waters, L.C, Muskett, F.W, Morgan, S, Lesley, A, Griffiths, M, Stubberfield, C, Griffin, R, Henry, A.J, Robinson, M.K, Jansson, A, Ladbury, J.E, Ikemizu, S, Davis, S.J, Carr, M.D. | | Deposit date: | 2012-12-18 | | Release date: | 2013-02-27 | | Last modified: | 2013-05-15 | | Method: | SOLUTION NMR | | Cite: | Structure and interactions of the human programmed cell death 1 receptor.
J.Biol.Chem., 288, 2013
|
|
2KH2
 | | Solution structure of a scFv-IL-1B complex | | Descriptor: | Interleukin-1 beta, scFv | | Authors: | Wilkinson, I.C, Hall, C.J, Veverka, V, Muskett, F.W, Stephens, P.E, Taylor, R.J, Henry, A.J, Carr, M.D. | | Deposit date: | 2009-03-23 | | Release date: | 2009-09-08 | | Last modified: | 2022-03-16 | | Method: | SOLUTION NMR | | Cite: | High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development.
J.Biol.Chem., 284, 2009
|
|
2K8P
 | | Characterisation of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation | | Descriptor: | Sclerostin | | Authors: | Veverka, V, Henry, A.J, Slocombe, P.M, Ventom, A, Mulloy, B, Muskett, F.W, Muzylak, M, Greenslade, K, Moore, A, Zhang, L, Gong, J, Qian, X, Paszty, C, Taylor, R.J, Robinson, M.K, Carr, M.D. | | Deposit date: | 2008-09-18 | | Release date: | 2009-02-17 | | Last modified: | 2022-03-16 | | Method: | SOLUTION NMR | | Cite: | Characterization of the Structural Features and Interactions of Sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation
J.Biol.Chem., 284, 2009
|
|
2L3Y
 | | Solution structure of mouse IL-6 | | Descriptor: | Interleukin-6 | | Authors: | Veverka, V, Redpath, N.T, Carrington, B, Muskett, F.W, Taylor, R.J, Henry, A.J, Carr, M.D. | | Deposit date: | 2010-09-25 | | Release date: | 2011-09-28 | | Last modified: | 2013-01-02 | | Method: | SOLUTION NMR | | Cite: | Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention.
J.Biol.Chem., 287, 2012
|
|
2KZT
 | | Structure of the Tandem MA-3 Region of Pdcd4 | | Descriptor: | Programmed cell death protein 4 | | Authors: | Waters, L.C, Strong, S.L, Oka, O, Muskett, F.W, Veverka, V, Banerjee, S, Schmedt, T, Henry, A.J, Klempnauer, K.H, Carr, M.D. | | Deposit date: | 2010-06-24 | | Release date: | 2011-03-16 | | Last modified: | 2011-11-23 | | Method: | SOLUTION NMR | | Cite: | Structure of the tandem MA-3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: molecular mechanisms of a tumor suppressor
J.Biol.Chem., 286, 2011
|
|
4J4P
 | | The complex of human IgE-Fc with two bound Fab fragments | | Descriptor: | Ig epsilon chain C region, Immunoglobulin G Fab Fragment Heavy Chain, Immunoglobulin G Fab Fragment Light Chain, ... | | Authors: | Drinkwater, N, Sutton, B.J. | | Deposit date: | 2013-02-07 | | Release date: | 2014-03-12 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.91 Å) | | Cite: | Human immunoglobulin E flexes between acutely bent and extended conformations.
Nat.Struct.Mol.Biol., 21, 2014
|
|
4EZM
 | | Crystal structure of the human IgE-Fc(epsilon)3-4 bound to its B cell receptor derCD23 | | Descriptor: | Ig epsilon chain C region, Low affinity immunoglobulin epsilon Fc receptor, alpha-D-mannopyranose, ... | | Authors: | Dhaliwal, B, Yuan, D, Sutton, B.J. | | Deposit date: | 2012-05-03 | | Release date: | 2012-07-18 | | Last modified: | 2023-09-13 | | Method: | X-RAY DIFFRACTION (3.1 Å) | | Cite: | Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc{varepsilon}RI.
Proc.Natl.Acad.Sci.USA, 109, 2012
|
|
2WQR
 | | The high resolution crystal structure of IgE Fc | | Descriptor: | 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, GLYCEROL, IG EPSILON CHAIN C REGION, ... | | Authors: | Dhaliwal, B, Sutton, B.J, Beavil, A.J. | | Deposit date: | 2009-08-26 | | Release date: | 2010-11-03 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (1.9 Å) | | Cite: | Conformational Changes in Ige Contribute to its Uniquely Slow Dissociation Rate from Receptor Fceri
Nat.Struct.Mol.Biol., 18, 2011
|
|
2Y7Q
 | | THE HIGH-AFFINITY COMPLEX BETWEEN IGE AND ITS RECEPTOR FC EPSILON RI | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, HIGH AFFINITY IMMUNOGLOBULIN EPSILON RECEPTOR SUBUNIT ALPHA, IG EPSILON CHAIN C REGION, ... | | Authors: | Davies, A.M, Holdom, M.D, Nettleship, J.E, Beavil, A.J, Owens, R.J, Sutton, B.J. | | Deposit date: | 2011-02-01 | | Release date: | 2011-04-20 | | Last modified: | 2023-12-20 | | Method: | X-RAY DIFFRACTION (3.4 Å) | | Cite: | Conformational Changes in Ige Contribute to its Uniquely Slow Dissociation Rate from Receptor Fceri
Nat.Struct.Mol.Biol., 18, 2011
|
|
5O57
 | | Solution Structure of the N-terminal Region of Dkk4 | | Descriptor: | Dickkopf-related protein 4 | | Authors: | Waters, L.C, Patel, S, Barkell, A.M, Muskett, F.W, Robinson, M.K, Holdsworth, G, Carr, M.D. | | Deposit date: | 2017-06-01 | | Release date: | 2018-06-13 | | Last modified: | 2023-06-14 | | Method: | SOLUTION NMR | | Cite: | Structural and functional analysis of Dickkopf 4 (Dkk4): New insights into Dkk evolution and regulation of Wnt signaling by Dkk and Kremen proteins.
J. Biol. Chem., 293, 2018
|
|
4DG6
 | | Crystal structure of domains 1 and 2 of LRP6 | | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Low-density lipoprotein receptor-related protein 6, PHOSPHATE ION | | Authors: | Ceska, T.A, Doyle, C, Slocombe, P. | | Deposit date: | 2012-01-25 | | Release date: | 2012-06-13 | | Last modified: | 2020-07-29 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Characterization of the interaction of sclerostin with the LRP family of Wnt co-receptors
To be Published
|
|
8CDG
 | | Crystal structure of human IL-17A cytokine in complex with macrocycle | | Descriptor: | (9~{S},12~{R},19~{S})-9-[[4-[[(2~{S})-2-cyclohexyl-2-(2-phenylethanoylamino)ethanoyl]amino]phenyl]methyl]-12-methyl-7,10,13,21-tetrakis(oxidanylidene)-8,11,14,20-tetrazaspiro[4.17]docosane-19-carboxylic acid, Interleukin-17A | | Authors: | Schulze, M.-S. | | Deposit date: | 2023-01-30 | | Release date: | 2023-12-06 | | Method: | X-RAY DIFFRACTION (2.9 Å) | | Cite: | Modulation of IL-17 backbone dynamics reduces receptor affinity and reveals a new inhibitory mechanism.
Chem Sci, 14, 2023
|
|
